2cureX

INTERIM REPORT H1 2026

THE POWER OF PRECISION FOR EVERY CANCER PATIENT.

INTERIM REPORT H1 2026

HIGHLIGHTS AND KEY FIGURES

The first half of 2026 was characterised by strengthened financing, active commercial development and continued commercial preparation for the next phase of the IndiTreat® platform. After the reporting period, the Company accelerated work concerning the future alignment of the 2cureX businesses and confirmed its intention to seek relisting on another appropriate marketplace.

- Oversubscribed financing: in April 2026, 2cureX announced an oversubscribed directed issue of up to 6,800,000 shares, with expected gross proceeds of approximately SEK 7.51 million before transaction costs. On 25 August 2026, the issue was registered and 6,541,736 new shares were issued.
- Patient access and tumour logistics: the Company entered a strategic collaboration with StoreMyTumor to support tumour logistics and patient coordination connected with Functional Precision Medicine.
- Hospital-led commercial model: work continued with 2cureX A/S to prepare the decentralised IndiTreat® workflow for initial hospital installations during the second half of 2026.
- Commercial engagement: management progressed hospital, clinical and partnership discussions and continued to develop a route to recurring product and service revenues.
- Governance and operating capability: the Company strengthened management, investor communication and execution resources while maintaining disciplined cost control.
- Potential combination: following the reporting period, the Company continued to evaluate a potential combination of 2cureX AB and 2cureX A/S. The final structure and timing remain under review and subject to the necessary legal and corporate processes.
- Future trading venue: following Nasdaq Stockholm’s decision to delist the shares from Nasdaq First North Growth Market, the Board confirmed its intention to seek relisting on another appropriate marketplace.

SIGNIFICANT EVENTS

FEBRUARY

Publication of the interim report for the second half of 2025.

APRIL

Announcement of an oversubscribed directed share issue of up to 6,800,000 shares, with expected gross proceeds of approximately SEK 7.51 million.

MAY

Strategic collaboration announced with StoreMyTumor to support tumour logistics and patient coordination activities associated with Functional Precision Medicine.

Management hosted a live shareholder and investor webcast on 20 May, presenting current progress, strategic priorities and upcoming milestones.Publication of the 2cureX AB Annual Report for 2025 on 28 May.

JUNE

Annual General Meeting held. Shareholders adopted the financial statements, resolved that no dividend would be paid, elected the Board and approved amendments to the Articles of Association.

The Company announced that the directed issue would be registered under the new issue authorisation granted by the Annual General Meeting on 25 June 2026, as the earlier authorisation could not be used due to administrative delays.

JULY — AFTER THE PERIOD

Nasdaq Stockholm raised questions concerning the Company's fulfilment of the ongoing-business requirement. 2cureX responded with an extensive evidence package covering financing, governance, commercial and clinical activity, assets, intellectual property, employees and the operating plan.

AUGUST — AFTER THE PERIOD

The Company advanced its work concerning a potential combination of 2cureX AB and 2cureX A/S. The final structure and timing remain under review and subject to the necessary legal and corporate processes.

Nasdaq Stockholm decided to delist 2cureX AB's shares from Nasdaq First North Growth Market, with the last trading day set for 31 August 2026. The Company does not agree with Nasdaq's assessment and is reviewing the decision and its available options with advisers. The Board intends to seek relisting on another appropriate marketplace.

On 21 August 2026, documentation for the registration of the directed issue was submitted to Bolagsverket. On 25 August 2026, Bolagsverket registered the issue and 6,541,736 new shares were issued, increasing the total number of shares from 25,102,916 to 31,644,652.

Continued focus: Management remains focused on business execution, financing, governance and preserving an appropriate public trading venue for shareholders.

LETTER FROM THE INTERIM CEO

BUILDING THE OPERATING PLATFORM

The first half of 2026 was a period of practical progress for 2cureX AB. We strengthened the company's financial position through an oversubscribed directed issue, advanced commercial and patient-access initiatives and continued working with partners to prepare IndiTreat® for a decentralised hospital model.

Our collaboration with StoreMyTumor extends the patient journey beyond the test itself. It provides a framework for tumour logistics and coordination, helping make functional precision medicine easier to access within the clinical pathway.

In parallel, our work with 2cureX A/S has focused on the operational, regulatory and quality steps required to bring the IndiTreat® workflow into the hospital laboratory.

After the reporting period, Nasdaq Stockholm decided that the company's shares would be delisted from nasdaq first north growth market. the company intends to seek relisting on another appropriate marketplace. our focus remains on maintaining continuity for shareholders while continuing to execute the company's operating and commercial plans.

2cureX AB and 2cureX A/S are evaluating a potential combination intended to bring together the IndiTreat® technology, people, laboratories, quality systems, intellectual property and commercialisation programme. The final structure, timing and implementation remain under review and subject to the necessary legal and corporate processes.

Our priorities are clear:

- Prepare the decentralised IndiTreat® platform for initial hospital installations.
- Convert hospital, clinical and partnership discussions into contracted activity.
- Maintain disciplined capital allocation and secure the financing required for commercial execution.
- Progress preparations for relisting on an alternative marketplace.

We enter the next phase with a defined operating plan, an experienced team and a technology designed to address a clear clinical need. Our focus remains on turning that foundation into sustainable value for patients, healthcare providers and shareholders.

Nathaniel Hutley

Interim CEO, 2cureX AB (publ)

NATHANIEL HUTLEY
INTERIM CEO, 2CUREX AB

BUSINESS AND STRATEGY

IndiTreat®

IndiTreat® is a functional precision oncology platform designed to support individualised cancer-treatment selection. Cancer cells obtained from a patient tumour biopsy are grown as three-dimensional microtumours, known as tumoroids, and tested against individual drugs and combination therapies. The resulting drug-sensitivity information is analysed and compiled into a report intended to support clinical decision-making.

From Centralised Testing to Hospital Deployment

Over the past two years, the Company's partner, the privately held 2cureX A/S, has developed IndiTreat® from a centralised laboratory service towards a decentralised model designed for deployment in hospital laboratories.

2cureX A/S is preparing for initial hospital installations during the second half of 2026. These installations are intended to validate the operational model and create reference sites for broader commercial deployment. Timing remains dependent on completion of site-level, contractual, operational and regulatory preparations.

Commercial Routes

- Centralised testing services where the decentralised model is not yet available.
- Patient-access and tumour-logistics pathways developed with partners such as StoreMyTumor and 2cureX A/S.
- Clinical and biopharmaceutical collaborations using patient-derived tumoroids and drug-sensitivity data.

Operating objective:

Create a scalable hospital-based platform in which direct-to-patient commercialisation develops into recurring revenue streams.

EXECUTION PROGRAMME

The Company’s work programme combines capital, commercial, clinical, technical and governance activity.

Commercial development

- Hospital engagement concerning decentralised IndiTreat® installations and implementation pathways.
- Patient-access and tumour-logistics collaboration with StoreMyTumor.
- Development of commercial propositions, pricing, contracting and onboarding materials.
- Evaluation of additional strategic partnerships and routes to market.

Corporate Execution

- Directed-issue financing announced during the period, together with active work on registration and future capital requirements.
- Ongoing investor relations, governance, financial reporting and adviser management.
- Evaluation of a potential combination of the 2cureX businesses and preparations for relisting on an alternative marketplace.
- Continued business planning and operational oversight.

POTENTIAL COMBINATION OF THE 2CUREX BUSINESSES

The original 2cureX group was built around 2cureX AB and its Danish operating subsidiary, 2cureX A/S. Following the 2024 restructuring, the listed company and operating business continued to collaborate, but ownership of 2cureX A/S sat outside the listed group through a private investment consortium (Precision ApS).

Since the spin-out of 2cureX A/S in 2024, the companies have continued to collaborate and consider how the two businesses could be brought closer together as 2cureX A/S moves towards deployment of the IndiTreat® platform in European hospitals. The companies continue to evaluate the most appropriate structure for a potential combination, alongside 2cureX AB's preparations for relisting on an alternative marketplace.

NASDAQ DELISTING AND FUTURE TRADING VENUE

In July 2026, Nasdaq Stockholm informed 2cureX AB of its preliminary assessment that the Company did not satisfy the ongoing-business requirement under item 2.3.7 of the Nasdaq First North Growth Market Rulebook. Nasdaq requested that the Company provide a comprehensive description and supporting evidence of its business operations by 14 August 2026.

The Company submitted material covering its financing, commercial and partnership activity, governance, operating resources and plans concerning a potential future combination of the 2cureX businesses. During its review, Nasdaq also raised the question of whether such a combination could constitute a substantial change requiring a new listing process.

On 17 August 2026, the Company was informed that Nasdaq Stockholm had decided, pursuant to item 8.2.7 of the Rulebook, to delist 2cureX AB's shares from Nasdaq First North Growth Market. The decision followed Nasdaq's assessment that the Company did not meet the ongoing-business requirement. The last day of trading is 31 August 2026.

2cureX AB does not agree with Nasdaq's assessment. The Company is reviewing the decision and process, together with its available legal and regulatory options, with its advisers.

The Board remains focused on maintaining the Company's operations, progressing its strategic initiatives and protecting shareholder interests. The Company is progressing preparations for relisting on an alternative marketplace. The process is advancing, and the Company will provide further information at the appropriate time.

FINANCIAL PERFORMANCE

In connection with the Company's transition to a new trading venue, the Board has decided to defer presentation of the financial figures for the reporting period. The Company is progressing its preparations for relisting on an alternative marketplace, and the financial figures will be provided as this process advances.

The Share

There is one class of shares in 2cureX AB (publ). As of 30 June 2026, the number of registered shares amounted to 25,102,916. The average number of shares during H1 2026 amounted to 25,102,916. In April 2026, the Company announced an oversubscribed directed issue of up to 6,800,000 shares. On 25 August 2026, Bolagsverket registered the issue and 6,541,736 new shares were issued, increasing the total number of shares to 31,644,652.

Accounting Policies and Review

2cureX AB applies the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3) in preparing its financial reports. This interim report has not been reviewed by the Company's auditor.

CORPORATE GOVERNANCE AND RISK

2cureX AB (publ) is a Swedish public limited company. During the reporting period, its shares were admitted to trading on Nasdaq First North Growth Market. Following the delisting decision, the Board continues to apply appropriate governance and disclosure procedures.

The Annual General Meeting held on 25 June 2026 resolved that the Board would comprise five members. Ole Thastrup, Grith Hagel and Nathaniel Hutley were re-elected, and Malgorzata Khrais and Jacob Scott were newly elected. Registration of the newly elected directors has not yet been completed. Until registration is completed, the registered Board remains Ole Thastrup, Grith Hagel, Nathaniel Hutley and Tonni Bülow-Nielsen.

Principal Risks and Uncertainties

- Financing and liquidity risk, including the Company's ability to fund the operating and commercialisation plan.
- Marketplace and liquidity risk following Nasdaq Stockholm's delisting decision and during any period before relisting on another venue.
- Transaction and structural risk relating to any potential combination of the 2cureX businesses, including required approvals and the possibility that its final structure, terms or timing may change.
- Commercial adoption risk, including hospital procurement cycles, validation requirements and the timing of recurring revenues.
- Dependence on key personnel, partners, suppliers and financing counterparties.
- Technology, intellectual-property, data-protection and clinical-performance risk.

The Board monitors these risks through financial oversight, documented workstreams, external legal and regulatory advice, partner engagement and ongoing review of the Company's strategy and funding requirements.

DELIVERY OF INTERIM REPORT

Landskrona, ___________________ 2026

2cureX AB (publ)

Board Of Directors

OLE THASTRUP
CHAIRMAN OF THE BOARD

GRITH HAGEL
BOARD MEMBER

NATHANIEL HUTLEY
BOARD MEMBER AND INTERIM CEO

TONNI BÜLOW-NIELSEN
BOARD MEMBER

The signatories above reflect the registered Board at the report date.

FINANCIAL CALENDAR

31 August 2026

LAST TRADING DAY ON NASDAQ FIRST NORTH

04 March 2027

INTERIM REPORT H2 2026 / FULL YEAR 2026

27 May 2027

ANNUAL REPORT 2026

24 June 2027

ANNUAL GENERAL MEETING 2027

THE POWER OF PRECISION FOR EVERY CANCER PATIENT.

2CUREX AB (publ)
Corporate registration number: 559128-0077
c/o Talenom Consulting AB
Lilla Strandgatan 19, 261 29 Landskrona, Sweden

Nathaniel Hutley, Interim CEO
Email: NH@2curex.se
Tel: +44 (776) 514 1346

Kenneth Graabek Johansen, CFO
Email: KGJ@2curex.com
Tel: +45 23 49 02 27

2cureX